JP2024536419A - レボチロキシンの注射可能な徐放性薬学的製剤およびその調製方法 - Google Patents

レボチロキシンの注射可能な徐放性薬学的製剤およびその調製方法 Download PDF

Info

Publication number
JP2024536419A
JP2024536419A JP2024521050A JP2024521050A JP2024536419A JP 2024536419 A JP2024536419 A JP 2024536419A JP 2024521050 A JP2024521050 A JP 2024521050A JP 2024521050 A JP2024521050 A JP 2024521050A JP 2024536419 A JP2024536419 A JP 2024536419A
Authority
JP
Japan
Prior art keywords
levothyroxine
pharmaceutical formulation
polymer
lactide
glycolide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024521050A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024536419A5 (https=
Inventor
エバンゲロス カラバス，
エフシミオス クトリス，
リダ カランツィ，
ソティリア チャイティドー，
ニコス レモナキス，
アンナ パパダキ，
ヴィンセント ブリューデス，
アルテミス カレジ，
アタナシオス カツェニス，
カテリーナ コッティ，
Original Assignee
ファーマシェン エス．エー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GR20210100683A external-priority patent/GR1010327B/el
Priority claimed from GB2119164.8A external-priority patent/GB2613656A/en
Application filed by ファーマシェン エス．エー． filed Critical ファーマシェン エス．エー．
Publication of JP2024536419A publication Critical patent/JP2024536419A/ja
Publication of JP2024536419A5 publication Critical patent/JP2024536419A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024521050A 2021-10-06 2022-10-06 レボチロキシンの注射可能な徐放性薬学的製剤およびその調製方法 Pending JP2024536419A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GR20210100683A GR1010327B (el) 2021-10-06 2021-10-06 Παρατεταμενης αποδεσμευσης ενεσιμο φαρμακευτικο σκευασμα λεβοθυροξινης και μεθοδος παρασκευης αυτου
GR20210100683 2021-10-06
GB2119164.8A GB2613656A (en) 2021-12-13 2021-12-13 Sustained release injectable pharmaceutical formulation of levothyroxine and process for preparation thereof
GB2119164.8 2021-12-13
PCT/EP2022/025463 WO2023057088A1 (en) 2021-10-06 2022-10-06 Sustained release injectable pharmaceutical formulation of levothyroxine and process for preparation thereof

Publications (2)

Publication Number Publication Date
JP2024536419A true JP2024536419A (ja) 2024-10-04
JP2024536419A5 JP2024536419A5 (https=) 2025-10-09

Family

ID=83996642

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024521050A Pending JP2024536419A (ja) 2021-10-06 2022-10-06 レボチロキシンの注射可能な徐放性薬学的製剤およびその調製方法

Country Status (10)

Country Link
US (1) US20250268830A1 (https=)
EP (1) EP4412594A1 (https=)
JP (1) JP2024536419A (https=)
KR (1) KR20240066197A (https=)
AU (1) AU2022360328A1 (https=)
CA (1) CA3234073A1 (https=)
CO (1) CO2024005798A2 (https=)
MX (1) MX2024004141A (https=)
WO (1) WO2023057088A1 (https=)
ZA (1) ZA202403411B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4701631A1 (en) * 2023-04-28 2026-03-04 Maia Pharmaceuticals, Inc. Levothyroxine dispersions
CN116831994B (zh) * 2023-06-25 2026-03-27 湖南赛隆药业(长沙)有限公司 一种注射用左甲状腺素钠缓释微球冻干制剂及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1127634A (zh) 1995-04-06 1996-07-31 中国科学院成都有机化学研究所 一种激素缓释微球注射剂及其制备方法
CN113384537A (zh) * 2021-04-25 2021-09-14 苏州大学 一种左旋千金藤啶碱缓释微球及其制备方法

Also Published As

Publication number Publication date
US20250268830A1 (en) 2025-08-28
CA3234073A1 (en) 2023-04-13
AU2022360328A1 (en) 2024-05-16
CO2024005798A2 (es) 2024-05-10
MX2024004141A (es) 2024-07-10
WO2023057088A1 (en) 2023-04-13
ZA202403411B (en) 2025-01-29
EP4412594A1 (en) 2024-08-14
KR20240066197A (ko) 2024-05-14

Similar Documents

Publication Publication Date Title
EP2394663B1 (en) Compositions for injectable in-situ biodegradable implants
US9155721B2 (en) Delayed release, oral dosage compositions that contain amorphous CDDO-Me
EP2982367B1 (en) Pharmaceutical composition for parenteral administration, containing donepezil
ES2798103T3 (es) Composición farmacéutica inyectable estable de antagonista del receptor de neuroquinina-1 y procedimiento para su preparación
JP6356064B2 (ja) 活性成分としてアポモルヒネを含む、新たな治療的組成物。
JP2013527213A5 (https=)
SG185775A1 (en) Antipsychotic injectable depot composition
CN114886850A (zh) 尼莫地平制剂及治疗病症的方法
JP2024536419A (ja) レボチロキシンの注射可能な徐放性薬学的製剤およびその調製方法
EA018203B1 (ru) Композиция пролонгированного высвобождения, содержащая памоат пасиреотида в микрочастицах с полимерной матрицей, способ получения микрочастиц и способ лечения
JP2023075278A (ja) 薬剤送達用生体溶解性医薬ゲル
CN108210461A (zh) 一种Talazoparib药物组合物及其应用
KR20220170782A (ko) 세마글루타이드 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 제제 조성물
CN102133180B (zh) 一种甾体5α-还原酶抑制剂长效注射制剂及其制备方法
CN109528632A (zh) 尼莫地平药物组合物、尼莫地平注射液及其制备方法
CN118201604A (zh) 左旋甲状腺素的缓释可注射药物制剂及其制备方法
HK40105344A (zh) 左旋甲状腺素的缓释可注射药物制剂及其制备方法
GB2613656A (en) Sustained release injectable pharmaceutical formulation of levothyroxine and process for preparation thereof
JP2005524642A (ja) ハロフジノンおよびその他のキナゾリノン誘導体の安定化医薬組成物
CA3117511C (en) Cyclodextrin-based formulation of a bcl-2 inhibitor
CN101502484A (zh) 同载糖皮质激素和化疗药物的抗癌缓释剂
HK40077176A (en) Nimodipine formulation and method of treating conditions
EP4721730A1 (en) Pharmaceutical composition comprising sustained-release microsphere comprising cagrilintide or pharmaceutically acceptable salt thereof and preparation method therefor
CN118043036A (zh) 包含他克莫司的药物制剂、其制备方法和用途
WO2026058187A1 (en) Long-acting parenteral formulations of tofacitinib and tofacitinib salts

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251001

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251001